REGENERON PHARMACEUTICALS, INC. Current Liabilities
REGENERON PHARMACEUTICALS, INC. (REGN) had Current Liabilities of $5.53 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Liabilities, Current $5.53B.
- 2026-03-31: Liabilities, Current $5.11B.
- 2025-12-31: Liabilities, Current $4.37B.
- 2025-09-30: Liabilities, Current $4.43B.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $5.53B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $5.11B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $4.37B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $4.43B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $3.67B 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $3.57B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $3.94B 10-K · filed 2026-02-04 | |
| 2024-09-30 | $3.66B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $3.51B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $3.58B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $3.42B 10-K · filed 2025-02-05 | |
| 2023-09-30 | $3.60B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $3.10B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $3.10B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $3.14B 10-K · filed 2024-02-05 | |
| 2022-09-30 | $2.88B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $3.03B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $3.01B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $3.93B 10-K · filed 2023-02-06 | |
| 2021-09-30 | $3.71B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $3.73B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $3.22B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $2.70B 10-K · filed 2022-02-07 | |
| 2020-09-30 | $2.34B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $3.70B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $2.06B 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $2.10B 10-K · filed 2021-02-08 | |
| 2019-09-30 | $1.77B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $1.71B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $1.51B 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $1.44B 10-K · filed 2020-02-07 | |
| 2018-09-30 | $1.42B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $1.33B 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $1.27B 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $1.14B 10-K · filed 2019-02-07 | $1.14B 10-K · filed 2018-02-08 |
| 2017-09-30 | $1.14B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $1.03B 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $1.31B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $1.24B 10-K · filed 2018-02-08 | |
| 2016-09-30 | $961.18M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $951.56M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $919.72M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $811.16M 10-K · filed 2017-02-09 | |
| 2015-09-30 | $734.99M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $601.54M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $536.13M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $654.66M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $410.20M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $351.58M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $305.07M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $298.83M 10-K · filed 2015-02-12 | |
| 2013-09-30 | $268.73M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $203.80M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $197.24M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $163.55M 10-K · filed 2014-02-13 | |
| 2012-09-30 | $178.57M 10-Q · filed 2012-10-24 | |
| 2012-06-30 | $183.22M 10-Q · filed 2012-07-25 | |
| 2012-03-31 | $160.39M 10-Q · filed 2012-04-26 | |
| 2011-12-31 | $148.27M 10-K · filed 2013-02-15 | |
| 2011-09-30 | $133.24M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $135.87M 10-Q · filed 2011-07-28 | |
| 2011-03-31 | $112.25M 10-Q · filed 2011-05-03 | |
| 2010-12-31 | $109.06M 10-K · filed 2012-02-21 | |
| 2010-09-30 | $133.83M 10-Q · filed 2010-10-28 | |
| 2010-06-30 | $119.57M 10-Q · filed 2010-07-28 | |
| 2009-12-31 | $93.58M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |